Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.